ASGCT 2025 at a glance

Count down to ASGCT 2025 with LucidQuest’s brief preview, guiding you through the essential sessions and evolving themes in gene and cell therapy and AI.

📅 Build your schedule around the topics that interest you. 📥 Download the ASGCT_2025_Preview_by_LucidQuest

Dive deeper

Key Topics From ASGCT 2025 Scientific Presentations

NeuroGene

• CRISPR-Cas13, AAV, and ASOs (HG204 for MDS; INS1201 & EXG001-307 for DMD/SMA) move rare neuro-/neuromuscular disorders from lab to clinic. 🧠⚡

OncoCAR-T

• GITRL-armed, PD-1-retaining, and anti-GD2/DLL3/MSLN/EPHB4 CAR-Ts pair with αPD-1 or oncolytic viruses to crack solid-tumor resistance. 🛡️🔥

Gene Antibodies

• DNA/AAV-encoded mAbs deliver 72-week SARS-CoV-2 neutralization and bNAb-mediated HIV control—no bioreactors required. 💉⏳

Metabolic Cures

• ECUR-506, DTX301, and ART002 (-91% PCSK9, -68% LDL-C) signal functional cures for OTCD, Fabry, and HeFH. 🩺🔧

Autoimmune

• CD19 CAR-T (CABA-201) drives drug-free remission in SLE & systemic sclerosis; MSC therapy TH-SC01 hits 50% fistula closure in refractory Crohn’s. ♻️🛡️

CardioGT

• AAV9 FT-017 rescues MYBPC3-HCM; CaMKII knock-down tames AF; CRISPR PCSK9 editing slashes LDL-C in a single IV dose. ❤️🖥️

Ophthalmology

• Subretinal CRISPR & AAV (HG202, FT-002) boost vision in nAMD, XLRP, and RP—even with pre-existing NAbs. 👁️✨

Clinical Ops

• Integration-site tracking (PACS1, RPTOR) links to durable CAR-T remission; NAb stratification optimizes AAV trial success. 📊🔍

Delivery Tech

• DGEUC-purified capsids, magnetic LV nanoparticles, and immune-evasive AAV-PD-L1 extend expression windows while keeping yields high. 📦🔒

Artificial Intelligence & Machine Learning at ASGCT 2025

CRISPR-GEM

• ML pinpoints PRG4 and BMP2 targets, turbo-charging MSC cartilage repair. 🤖🦴

AI Capsids

• In-silico designs yield 200× kidney-selective AAVs. 🧠🔬

Treg Scale-Up

• AI-optimized G-Rex expands Tregs ×7.9 with 93% viability for trials. 🌱🧫

Vector QC

• Nanoneedle + ML “Tessie” platform maps AAV genome integrity without miscalls. 📏🧰

Drug Discovery

• AI-generated libraries boost hit diversity 10²–10³× vs. classic screening. 🧪🚀

Microfluidics

• AI-guided chips hit >95% HSC edit efficiency with minimal toxicity. 💉🔄

📅 Build your schedule around the topics that interest you.

📥 Download the ASGCT_2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.